APO Research
Talk to an analyst

APO RESEARCH · REPORT

Nut Allergy Therapeutics

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Nut Allergy Therapeutics Market Outlook and Growth Opportunities 2026

2 January 2026197 pages

Choose your research edition.

Industry ResearchNut Allergy Therapeutics Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Nut Allergy Therapeutics Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Nut Allergy Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Nut Allergy Therapeutics Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Nut Allergy Therapeutics Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Nut Allergy Therapeutics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Nut Allergy Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Nut Allergy Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Nut Allergy Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Nut Allergy Therapeutics market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Nut Allergy Therapeutics market include J & J, HUAPONT Pharm, GSK, Bayer, Viatris, UCB Pharma, Perrigo, Kaleo and Amneal Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Nut Allergy Therapeutics market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Nut Allergy Therapeutics and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Nut Allergy Therapeutics revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Nut Allergy Therapeutics market.

Nut Allergy Therapeutics Segment by Company

J & J

HUAPONT Pharm

GSK

Bayer

Viatris

UCB Pharma

Perrigo

Kaleo

Amneal Pharma

ALK Abello

Aimmune Therapeutics

Nut Allergy Therapeutics Segment by Type

Epinephrine Injection

Antihistamines

Other

Nut Allergy Therapeutics Segment by Application

Hospital Pharmacy

Retail Pharmacy

Other

Nut Allergy Therapeutics Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Nut Allergy Therapeutics status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Nut Allergy Therapeutics key companies, revenue, market share, and recent developments.

3. To split the Nut Allergy Therapeutics breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Nut Allergy Therapeutics market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Nut Allergy Therapeutics significant trends, drivers, influence factors in global and regions.

6. To analyze Nut Allergy Therapeutics competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nut Allergy Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Nut Allergy Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nut Allergy Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Nut Allergy Therapeutics industry.

Chapter 3: Detailed analysis of Nut Allergy Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Nut Allergy Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Nut Allergy Therapeutics in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Nut Allergy Therapeutics Industry Trends Table 2. Nut Allergy Therapeutics Industry Drivers Table 3. Nut Allergy Therapeutics Industry Opportunities and Challenges Table 4. Nut Allergy Therapeutics Industry Restraints Table 5. Global Nut Allergy Therapeutics Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Nut Allergy Therapeutics Revenue Share by Company (2021-2026) Table 7. Global Nut Allergy Therapeutics Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Nut Allergy Therapeutics Key Company Manufacturing Base & Headquarters Table 9. Global Nut Allergy Therapeutics Company, Product Type & Application Table 10. Global Nut Allergy Therapeutics Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Nut Allergy Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Epinephrine Injection Table 15. Significant Companies of Antihistamines Table 16. Significant Companies of Other Table 17. Global Nut Allergy Therapeutics Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Nut Allergy Therapeutics Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Nut Allergy Therapeutics Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Nut Allergy Therapeutics Sales Value Share by Type (2021-2026) Table 21. Global Nut Allergy Therapeutics Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Hospital Pharmacy Table 23. Significant Companies of Retail Pharmacy Table 24. Significant Companies of Other Table 25. Global Nut Allergy Therapeutics Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Nut Allergy Therapeutics Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Nut Allergy Therapeutics Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Nut Allergy Therapeutics Sales Value Share by Application (2021-2026) Table 29. Global Nut Allergy Therapeutics Sales Value Share by Application (2027-2032) Table 30. Global Nut Allergy Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Nut Allergy Therapeutics Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Nut Allergy Therapeutics Sales Value Share by Region (2021-2026) Table 33. Global Nut Allergy Therapeutics Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Nut Allergy Therapeutics Sales Value Share by Region (2027-2032) Table 35. Global Nut Allergy Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Nut Allergy Therapeutics Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Nut Allergy Therapeutics Sales Value Market Share by Country (2021-2026) Table 38. Global Nut Allergy Therapeutics Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Nut Allergy Therapeutics Sales Value Market Share by Country (2027-2032) Table 40. J & J Company Information Table 41. J & J Business Overview Table 42. J & J Nut Allergy Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. J & J Nut Allergy Therapeutics Product Portfolio Table 44. J & J Recent Development Table 45. HUAPONT Pharm Company Information Table 46. HUAPONT Pharm Business Overview Table 47. HUAPONT Pharm Nut Allergy Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. HUAPONT Pharm Nut Allergy Therapeutics Product Portfolio Table 49. HUAPONT Pharm Recent Development Table 50. GSK Company Information Table 51. GSK Business Overview Table 52. GSK Nut Allergy Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. GSK Nut Allergy Therapeutics Product Portfolio Table 54. GSK Recent Development Table 55. Bayer Company Information Table 56. Bayer Business Overview Table 57. Bayer Nut Allergy Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Bayer Nut Allergy Therapeutics Product Portfolio Table 59. Bayer Recent Development Table 60. Viatris Company Information Table 61. Viatris Business Overview Table 62. Viatris Nut Allergy Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Viatris Nut Allergy Therapeutics Product Portfolio Table 64. Viatris Recent Development Table 65. UCB Pharma Company Information Table 66. UCB Pharma Business Overview Table 67. UCB Pharma Nut Allergy Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. UCB Pharma Nut Allergy Therapeutics Product Portfolio Table 69. UCB Pharma Recent Development Table 70. Perrigo Company Information Table 71. Perrigo Business Overview Table 72. Perrigo Nut Allergy Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Perrigo Nut Allergy Therapeutics Product Portfolio Table 74. Perrigo Recent Development Table 75. Kaleo Company Information Table 76. Kaleo Business Overview Table 77. Kaleo Nut Allergy Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Kaleo Nut Allergy Therapeutics Product Portfolio Table 79. Kaleo Recent Development Table 80. Amneal Pharma Company Information Table 81. Amneal Pharma Business Overview Table 82. Amneal Pharma Nut Allergy Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Amneal Pharma Nut Allergy Therapeutics Product Portfolio Table 84. Amneal Pharma Recent Development Table 85. ALK Abello Company Information Table 86. ALK Abello Business Overview Table 87. ALK Abello Nut Allergy Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. ALK Abello Nut Allergy Therapeutics Product Portfolio Table 89. ALK Abello Recent Development Table 90. Aimmune Therapeutics Company Information Table 91. Aimmune Therapeutics Business Overview Table 92. Aimmune Therapeutics Nut Allergy Therapeutics Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Aimmune Therapeutics Nut Allergy Therapeutics Product Portfolio Table 94. Aimmune Therapeutics Recent Development Table 95. Research Programs/Design for This Report Table 96. Authors List of This Report Table 97. Secondary Sources Table 98. Primary Sources List of Figures Figure 1. Nut Allergy Therapeutics Product Image Figure 2. Global Nut Allergy Therapeutics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Nut Allergy Therapeutics Market Size (2021-2032) & (US$ Million) Figure 4. Global Nut Allergy Therapeutics Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Epinephrine Injection Image Figure 8. Antihistamines Image Figure 9. Other Image Figure 10. Global Nut Allergy Therapeutics Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Nut Allergy Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Nut Allergy Therapeutics Sales Value Share by Type (2021-2032) Figure 13. Hospital Pharmacy Image Figure 14. Retail Pharmacy Image Figure 15. Other Image Figure 16. Global Nut Allergy Therapeutics Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Nut Allergy Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Nut Allergy Therapeutics Sales Value Share by Application (2021-2032) Figure 19. Global Nut Allergy Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Nut Allergy Therapeutics Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Nut Allergy Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 22. North America Nut Allergy Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Nut Allergy Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Nut Allergy Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Nut Allergy Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Nut Allergy Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Nut Allergy Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 28. South America Nut Allergy Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Nut Allergy Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Nut Allergy Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Nut Allergy Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Nut Allergy Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Nut Allergy Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Nut Allergy Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Nut Allergy Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Nut Allergy Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Nut Allergy Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Nut Allergy Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Nut Allergy Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Nut Allergy Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Nut Allergy Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Nut Allergy Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Nut Allergy Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Nut Allergy Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Nut Allergy Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Nut Allergy Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Nut Allergy Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Nut Allergy Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Nut Allergy Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Nut Allergy Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Nut Allergy Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Nut Allergy Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Nut Allergy Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Nut Allergy Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Nut Allergy Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Nut Allergy Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Nut Allergy Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Nut Allergy Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Nut Allergy Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Nut Allergy Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Nut Allergy Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Nut Allergy Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Nut Allergy Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Nut Allergy Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Nut Allergy Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Nut Allergy Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Nut Allergy Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Nut Allergy Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Nut Allergy Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Nut Allergy Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Nut Allergy Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Nut Allergy Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Nut Allergy Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Nut Allergy Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Nut Allergy Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Nut Allergy Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Nut Allergy Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Nut Allergy Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Nut Allergy Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Nut Allergy Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Nut Allergy Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Nut Allergy Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Nut Allergy Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Nut Allergy Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Nut Allergy Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Nut Allergy Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Nut Allergy Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Nut Allergy Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Nut Allergy Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Nut Allergy Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Nut Allergy Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Nut Allergy Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Nut Allergy Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Nut Allergy Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Nut Allergy Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Nut Allergy Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Nut Allergy Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Nut Allergy Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Nut Allergy Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Nut Allergy Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Nut Allergy Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Nut Allergy Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Nut Allergy Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Nut Allergy Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Nut Allergy Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Nut Allergy Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Nut Allergy Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Nut Allergy Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Nut Allergy Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Nut Allergy Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Nut Allergy Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Nut Allergy Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Nut Allergy Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Nut Allergy Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Epinephrine Injection
  • Antihistamines
  • Other
Applications
  • Hospital Pharmacy
  • Retail Pharmacy
  • Other
Companies covered
  • J & J
  • HUAPONT Pharm
  • GSK
  • Bayer
  • Viatris
  • UCB Pharma
  • Perrigo
  • Kaleo
  • Amneal Pharma
  • ALK Abello
  • Aimmune Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Nut Allergy Therapeutics Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Nut Allergy Therapeutics Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Nut Allergy Therapeutics Market Dynamics
  1. 2.1 Nut Allergy Therapeutics Industry Trends
  2. 2.2 Nut Allergy Therapeutics Industry Drivers
  3. 2.3 Nut Allergy Therapeutics Industry Opportunities and Challenges
  4. 2.4 Nut Allergy Therapeutics Industry Restraints
3 Nut Allergy Therapeutics Market by Company
  1. 3.1 Global Nut Allergy Therapeutics Company Revenue Ranking in 2025
  2. 3.2 Global Nut Allergy Therapeutics Revenue by Company (2021-2026)
  3. 3.3 Global Nut Allergy Therapeutics Company Ranking (2024-2026)
  4. 3.4 Global Nut Allergy Therapeutics Company Manufacturing Base and Headquarters
  5. 3.5 Global Nut Allergy Therapeutics Company Product Type and Application
  6. 3.6 Global Nut Allergy Therapeutics Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Nut Allergy Therapeutics Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Nut Allergy Therapeutics Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Nut Allergy Therapeutics Market by Type
  1. 4.1 Nut Allergy Therapeutics Type Introduction
  2. 4.1.1 Epinephrine Injection
  3. 4.1.2 Antihistamines
  4. 4.1.3 Other
  5. 4.2 Global Nut Allergy Therapeutics Sales Value by Type
  6. 4.2.1 Global Nut Allergy Therapeutics Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Nut Allergy Therapeutics Sales Value by Type (2021-2032)
  8. 4.2.3 Global Nut Allergy Therapeutics Sales Value Share by Type (2021-2032)
5 Nut Allergy Therapeutics Market by Application
  1. 5.1 Nut Allergy Therapeutics Application Introduction
  2. 5.1.1 Hospital Pharmacy
  3. 5.1.2 Retail Pharmacy
  4. 5.1.3 Other
  5. 5.2 Global Nut Allergy Therapeutics Sales Value by Application
  6. 5.2.1 Global Nut Allergy Therapeutics Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Nut Allergy Therapeutics Sales Value by Application (2021-2032)
  8. 5.2.3 Global Nut Allergy Therapeutics Sales Value Share by Application (2021-2032)
6 Nut Allergy Therapeutics Regional Value Analysis
  1. 6.1 Global Nut Allergy Therapeutics Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Nut Allergy Therapeutics Sales Value by Region (2021-2032)
  3. 6.2.1 Global Nut Allergy Therapeutics Sales Value by Region: 2021-2026
  4. 6.2.2 Global Nut Allergy Therapeutics Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Nut Allergy Therapeutics Sales Value (2021-2032)
  7. 6.3.2 North America Nut Allergy Therapeutics Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Nut Allergy Therapeutics Sales Value (2021-2032)
  10. 6.4.2 Europe Nut Allergy Therapeutics Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Nut Allergy Therapeutics Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Nut Allergy Therapeutics Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Nut Allergy Therapeutics Sales Value (2021-2032)
  16. 6.6.2 South America Nut Allergy Therapeutics Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Nut Allergy Therapeutics Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Nut Allergy Therapeutics Sales Value Share by Country, 2025 VS 2032
7 Nut Allergy Therapeutics Country-level Value Analysis
  1. 7.1 Global Nut Allergy Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Nut Allergy Therapeutics Sales Value by Country (2021-2032)
  3. 7.2.1 Global Nut Allergy Therapeutics Sales Value by Country (2021-2026)
  4. 7.2.2 Global Nut Allergy Therapeutics Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Nut Allergy Therapeutics Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Nut Allergy Therapeutics Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Nut Allergy Therapeutics Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Nut Allergy Therapeutics Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Nut Allergy Therapeutics Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Nut Allergy Therapeutics Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Nut Allergy Therapeutics Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Nut Allergy Therapeutics Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Nut Allergy Therapeutics Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Nut Allergy Therapeutics Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Nut Allergy Therapeutics Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Nut Allergy Therapeutics Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Nut Allergy Therapeutics Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Nut Allergy Therapeutics Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Nut Allergy Therapeutics Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Nut Allergy Therapeutics Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Nut Allergy Therapeutics Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Nut Allergy Therapeutics Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Nut Allergy Therapeutics Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Nut Allergy Therapeutics Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Nut Allergy Therapeutics Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Nut Allergy Therapeutics Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Nut Allergy Therapeutics Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Nut Allergy Therapeutics Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Nut Allergy Therapeutics Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Nut Allergy Therapeutics Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Nut Allergy Therapeutics Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Nut Allergy Therapeutics Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Nut Allergy Therapeutics Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Nut Allergy Therapeutics Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Nut Allergy Therapeutics Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Nut Allergy Therapeutics Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Nut Allergy Therapeutics Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Nut Allergy Therapeutics Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Nut Allergy Therapeutics Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Nut Allergy Therapeutics Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Nut Allergy Therapeutics Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Nut Allergy Therapeutics Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Nut Allergy Therapeutics Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Nut Allergy Therapeutics Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Nut Allergy Therapeutics Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Nut Allergy Therapeutics Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Nut Allergy Therapeutics Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Nut Allergy Therapeutics Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Nut Allergy Therapeutics Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Nut Allergy Therapeutics Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Nut Allergy Therapeutics Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Nut Allergy Therapeutics Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Nut Allergy Therapeutics Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Nut Allergy Therapeutics Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Nut Allergy Therapeutics Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Nut Allergy Therapeutics Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Nut Allergy Therapeutics Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Nut Allergy Therapeutics Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Nut Allergy Therapeutics Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Nut Allergy Therapeutics Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Nut Allergy Therapeutics Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Nut Allergy Therapeutics Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Nut Allergy Therapeutics Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Nut Allergy Therapeutics Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Nut Allergy Therapeutics Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Nut Allergy Therapeutics Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Nut Allergy Therapeutics Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Nut Allergy Therapeutics Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Nut Allergy Therapeutics Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Nut Allergy Therapeutics Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Nut Allergy Therapeutics Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Nut Allergy Therapeutics Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Nut Allergy Therapeutics Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Nut Allergy Therapeutics Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Nut Allergy Therapeutics Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Nut Allergy Therapeutics Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Nut Allergy Therapeutics Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Nut Allergy Therapeutics Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Nut Allergy Therapeutics Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Nut Allergy Therapeutics Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Nut Allergy Therapeutics Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Nut Allergy Therapeutics Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Nut Allergy Therapeutics Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Nut Allergy Therapeutics Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Nut Allergy Therapeutics Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Nut Allergy Therapeutics Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Nut Allergy Therapeutics Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Nut Allergy Therapeutics Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 J & J
  2. 8.1.1 J & J Company Information
  3. 8.1.2 J & J Business Overview
  4. 8.1.3 J & J Nut Allergy Therapeutics Revenue and Gross Margin (2021-2026)
  5. 8.1.4 J & J Nut Allergy Therapeutics Product Portfolio
  6. 8.1.5 J & J Recent Developments
  7. 8.2 HUAPONT Pharm
  8. 8.2.1 HUAPONT Pharm Company Information
  9. 8.2.2 HUAPONT Pharm Business Overview
  10. 8.2.3 HUAPONT Pharm Nut Allergy Therapeutics Revenue and Gross Margin (2021-2026)
  11. 8.2.4 HUAPONT Pharm Nut Allergy Therapeutics Product Portfolio
  12. 8.2.5 HUAPONT Pharm Recent Developments
  13. 8.3 GSK
  14. 8.3.1 GSK Company Information
  15. 8.3.2 GSK Business Overview
  16. 8.3.3 GSK Nut Allergy Therapeutics Revenue and Gross Margin (2021-2026)
  17. 8.3.4 GSK Nut Allergy Therapeutics Product Portfolio
  18. 8.3.5 GSK Recent Developments
  19. 8.4 Bayer
  20. 8.4.1 Bayer Company Information
  21. 8.4.2 Bayer Business Overview
  22. 8.4.3 Bayer Nut Allergy Therapeutics Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Bayer Nut Allergy Therapeutics Product Portfolio
  24. 8.4.5 Bayer Recent Developments
  25. 8.5 Viatris
  26. 8.5.1 Viatris Company Information
  27. 8.5.2 Viatris Business Overview
  28. 8.5.3 Viatris Nut Allergy Therapeutics Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Viatris Nut Allergy Therapeutics Product Portfolio
  30. 8.5.5 Viatris Recent Developments
  31. 8.6 UCB Pharma
  32. 8.6.1 UCB Pharma Company Information
  33. 8.6.2 UCB Pharma Business Overview
  34. 8.6.3 UCB Pharma Nut Allergy Therapeutics Revenue and Gross Margin (2021-2026)
  35. 8.6.4 UCB Pharma Nut Allergy Therapeutics Product Portfolio
  36. 8.6.5 UCB Pharma Recent Developments
  37. 8.7 Perrigo
  38. 8.7.1 Perrigo Company Information
  39. 8.7.2 Perrigo Business Overview
  40. 8.7.3 Perrigo Nut Allergy Therapeutics Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Perrigo Nut Allergy Therapeutics Product Portfolio
  42. 8.7.5 Perrigo Recent Developments
  43. 8.8 Kaleo
  44. 8.8.1 Kaleo Company Information
  45. 8.8.2 Kaleo Business Overview
  46. 8.8.3 Kaleo Nut Allergy Therapeutics Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Kaleo Nut Allergy Therapeutics Product Portfolio
  48. 8.8.5 Kaleo Recent Developments
  49. 8.9 Amneal Pharma
  50. 8.9.1 Amneal Pharma Company Information
  51. 8.9.2 Amneal Pharma Business Overview
  52. 8.9.3 Amneal Pharma Nut Allergy Therapeutics Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Amneal Pharma Nut Allergy Therapeutics Product Portfolio
  54. 8.9.5 Amneal Pharma Recent Developments
  55. 8.10 ALK Abello
  56. 8.10.1 ALK Abello Company Information
  57. 8.10.2 ALK Abello Business Overview
  58. 8.10.3 ALK Abello Nut Allergy Therapeutics Revenue and Gross Margin (2021-2026)
  59. 8.10.4 ALK Abello Nut Allergy Therapeutics Product Portfolio
  60. 8.10.5 ALK Abello Recent Developments
  61. 8.11 Aimmune Therapeutics
  62. 8.11.1 Aimmune Therapeutics Company Information
  63. 8.11.2 Aimmune Therapeutics Business Overview
  64. 8.11.3 Aimmune Therapeutics Nut Allergy Therapeutics Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Aimmune Therapeutics Nut Allergy Therapeutics Product Portfolio
  66. 8.11.5 Aimmune Therapeutics Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst